Document Detail


The risks and benefits of drug-eluting stents in the setting of STEMI.
MedLine Citation:
PMID:  18715537     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Primary percutaneous coronary intervention (PCI) represents the treatment of choice in patients with ST-segment elevation myocardial infarction (STEMI). In randomized trials excluding STEMI patients, using drug-eluting stents (DES) significantly reduced angiographic restenosis and target vessel revascularization compared with bare metal stents (BMS); however, concerns exist regarding an increased follow-up incidence of stent thrombosis after DES implantation. This complication, which is associated with higher mortality and morbidity rates, may be more frequent among STEMI patients receiving DES versus BMS. Various registries, randomized trials, and two recent meta-analyses on patients undergoing primary PCI have shown that using DES is safe and is associated with significantly reduced rates of restenosis and repeat intervention without an increased risk of myocardial infarction or stent thrombosis at intermediate-term follow-up. However, large trials with hard clinical end points and longer follow-up are needed before routine DES use can be recommended in patients undergoing primary PCI.
Authors:
Rosetta Melfi; Annunziata Nusca; Giuseppe Patti; Germano Di Sciascio
Related Documents :
11893827 - Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the re...
1954687 - Restenosis following coronary angioplasty.
10956297 - Clinical and angiographic outcome in patients with in-stent restenosis and repeat targe...
12914867 - Evaluation of the american college of cardiology/american heart association and the soc...
12117607 - Intraventricular dispersion and temporal delay of early left ventricular filling after ...
19964637 - Spontaneous termination of atrial fibrillation: study of the effect of atrial geometry ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current cardiology reports     Volume:  10     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-08-21     Completed Date:  2008-12-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  402-6     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Sciences, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary
Drug-Eluting Stents* / adverse effects
Humans
Meta-Analysis as Topic
Metals
Myocardial Infarction / therapy*
Randomized Controlled Trials as Topic
Thrombosis / etiology
Time Factors
Chemical
Reg. No./Substance:
0/Metals

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Putting the benefits of percutaneous coronary revascularization into perspective: from trials to gui...
Next Document:  Percutaneous coronary intervention without onsite surgical backup.